AngioDynamics Story

<div class='circular--portrait' style='background:#754DEB;color: #F0FFF0;font-size:5em;'>A</div>
ANGO -- USA Stock  

USD 10.91  0.16  1.45%

AngioDynamics Market Capitalization is quite stable at the moment as compared to the past year. The company's current value of Market Capitalization is estimated at 485.49 Million. Tangible Asset Value is expected to rise to about 241.7 M this year, although the value of Net Income Per Employee will most likely fall to (213.4 K). In this post, we will outline AngioDynamics. What exactly are AngioDynamics shareholders getting in October? In this post, I will also go over some essential variables affecting AngioDynamics' products, and show how it may impact AngioDynamics outlook for active traders this year.
Published over three weeks ago
View all stories for AngioDynamics | View All Stories
AngioDynamics (NASDAQ:ANGO) continues to rise
On a scale of 0 to 100, AngioDynamics holds a performance score of 7. The firm shows a Beta (market volatility) of 0.4359, which signifies possible diversification benefits within a given portfolio. Let's try to break down what AngioDynamics's beta means in this case. As returns on the market increase, AngioDynamics returns are expected to increase less than the market. However, during the bear market, the loss on holding AngioDynamics will be expected to be smaller as well. Although it is vital to follow AngioDynamics historical returns, it is good to be conservative about what you can do with the information regarding equity current trending patterns. The philosophy in foreseeing future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. By analyzing AngioDynamics technical indicators, you can presently evaluate if the expected return of 0.42% will be sustainable into the future. Please makes use of AngioDynamics value at risk, and the relationship between the jensen alpha and skewness to make a quick decision on whether AngioDynamics price patterns will revert.

How important is AngioDynamics's Liquidity

AngioDynamics financial leverage refers to using borrowed capital as a funding source to finance AngioDynamics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. AngioDynamics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between AngioDynamics's total debt and its cash.

How AngioDynamics utilizes its cash?

To perform a cash flow analysis of AngioDynamics, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash AngioDynamics is receiving and how much cash it distributes out in a given period. The AngioDynamics cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. AngioDynamics Net Cash Flow from Operations is quite stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at (14.94 Million)

What did AngioDynamics file with SEC?

The SEC filings are financial statements or other formal documents of AngioDynamics that are regularly submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make SEC filings and fintech professionals rely on these filings for information about companies they are evaluating for investment purposes. Please note, most SEC filings are available online through the SEC's EDGAR database. Please check here for more information.
Please note, although all public domestic companies are required to submit their filings via EDGAR, not all public companies are available through our service. Also, keep in mind that the actual annual reports to AngioDynamics shareholders may or may not be submitted as SEC does not always require it.
Financial Statements and Exhibits. Submission of Matters to a Vote of Security Holders. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
Please note, although all public domestic companies are required to submit their filings via EDGAR, not all public companies are available through our service. Also, keep in mind that the actual annual reports to AngioDynamics shareholders may or may not be submitted as SEC does not always require it.

Acquisition by Tarnoff Michael E of 15323 shares of AngioDynamics subject to Rule 16b-3

Legal trades by AngioDynamics insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
AngioDynamics insider trading alert for grant of common stock by Tarnoff Michael E, the corporate stakeholder, on 16th of September 2020. This event was filed by Angiodynamics Inc with SEC on 2020-09-16. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

A Deeper look at AngioDynamics

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. AngioDynamics has an asset utilization ratio of 36.38 percent. This suggests that the company is making $0.36 for each dollar of assets. An increasing asset utilization means that AngioDynamics is more efficient with each dollar of assets it utilizes for everyday operations.
 2017 2019 2020 (projected)
Long Term Debt to Equity0.160.08790.11
Interest Coverage3.453.12.76

Our perspective of the latest AngioDynamics rise

The standard deviation is down to 2.96 as of today. As of the 29th of September, AngioDynamics shows the risk adjusted performance of 0.0471, and Mean Deviation of 2.09. AngioDynamics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down and interpolate data for nineteen technical drivers for AngioDynamics, which can be compared to its rivals. Please confirm AngioDynamics variance, as well as the relationship between the value at risk and skewness to decide if AngioDynamics is priced correctly, providing market reflects its regular price of 12.74 per share. Given that AngioDynamics has jensen alpha of 0.0582, we suggest you to validate AngioDynamics's prevailing market performance to make sure the company can sustain itself at a future point.

Our Conclusion on AngioDynamics

Whereas some other firms under the medical instruments & supplies industry are still a bit expensive, AngioDynamics may offer a potential longer-term growth to institutional investors. To conclude, as of the 29th of September 2020, our analysis shows that AngioDynamics moves indifferently to market moves. The company is overvalued and projects low probability of bankruptcy for the next 2 years. Our final 30 days buy-hold-sell advice on the company is Cautious Hold.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of AngioDynamics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com